CN104736143A - 具有降低的肾脏毒性的用于癌症治疗的改善方法 - Google Patents

具有降低的肾脏毒性的用于癌症治疗的改善方法 Download PDF

Info

Publication number
CN104736143A
CN104736143A CN201280075225.2A CN201280075225A CN104736143A CN 104736143 A CN104736143 A CN 104736143A CN 201280075225 A CN201280075225 A CN 201280075225A CN 104736143 A CN104736143 A CN 104736143A
Authority
CN
China
Prior art keywords
cancer
tumor
lipoplatin
cells
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280075225.2A
Other languages
English (en)
Chinese (zh)
Inventor
特尼·波利卡斯
乔治·斯塔索波罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN104736143A publication Critical patent/CN104736143A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201280075225.2A 2012-08-13 2012-08-13 具有降低的肾脏毒性的用于癌症治疗的改善方法 Pending CN104736143A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/050630 WO2014027996A1 (en) 2012-08-13 2012-08-13 Improved methods for treating cancer with reduced renal toxicity

Publications (1)

Publication Number Publication Date
CN104736143A true CN104736143A (zh) 2015-06-24

Family

ID=50101360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280075225.2A Pending CN104736143A (zh) 2012-08-13 2012-08-13 具有降低的肾脏毒性的用于癌症治疗的改善方法

Country Status (13)

Country Link
US (1) US20150258140A1 (enExample)
EP (1) EP2882420A4 (enExample)
JP (1) JP2015528446A (enExample)
CN (1) CN104736143A (enExample)
AU (1) AU2012387681A1 (enExample)
BR (1) BR112015003111A2 (enExample)
CA (1) CA2882156A1 (enExample)
EA (1) EA201590325A1 (enExample)
IN (1) IN2015KN00375A (enExample)
MA (1) MA37931A1 (enExample)
SG (1) SG11201501146VA (enExample)
WO (1) WO2014027996A1 (enExample)
ZA (1) ZA201501123B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2654484C1 (ru) * 2012-05-11 2018-05-21 Ресет Терапьютикс, Инк. Карбазолсодержащие сульфонамиды в качестве модуляторов криптохрома

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04169532A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体含有リポソーム製剤
JPH04169531A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体を含有するリポソーム製剤
EP0551169A1 (en) * 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
EP0929293B1 (en) * 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
DE19954613A1 (de) * 1999-11-12 2001-05-17 Enthone Omi Deutschland Gmbh Verfahren zur stromlosen Verzinnung von Kupfer oder Kupferlegierungen
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
US20120197060A1 (en) * 2009-06-18 2012-08-02 University Of Utah Research Foundation Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy technology

Also Published As

Publication number Publication date
BR112015003111A2 (pt) 2017-10-10
SG11201501146VA (en) 2015-05-28
JP2015528446A (ja) 2015-09-28
WO2014027996A1 (en) 2014-02-20
MA37931A1 (fr) 2016-07-29
EP2882420A1 (en) 2015-06-17
EP2882420A4 (en) 2016-06-01
ZA201501123B (en) 2020-02-26
US20150258140A1 (en) 2015-09-17
CA2882156A1 (en) 2014-02-20
IN2015KN00375A (enExample) 2015-07-10
EA201590325A1 (ru) 2015-09-30
AU2012387681A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
JP2022009090A (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
JP2024529976A (ja) がんを治療する方法
JP2022027993A (ja) リポソーム製剤のためのｐ－エトキシ核酸
CN102405044A (zh) 含有单萜的治疗组合物
KR20250027777A (ko) 암을 치료하기 위한 kras g12c 억제제
KR20190053905A (ko) 리포솜 안티센스 올리고뉴클레오타이드와의 병용 요법
AU2023275776A1 (en) Gcn2 modulator for treating cancer
BR112021011493A2 (pt) Terapia de combinação para tratamento de câncer
CN104736143A (zh) 具有降低的肾脏毒性的用于癌症治疗的改善方法
US20140296265A1 (en) Method of Treating Lymphoma Using Pyridopyrimidinone Inhibitors of PI3K/mTOR
JP2023515010A (ja) 免疫原性細胞死を促進するためのｍｉＲＮＡ－１９３ａ
US9745583B2 (en) Liposome for topical administration and application thereof
CN118043053A (zh) 治疗癌症的方法
JP2017178960A (ja) 腎毒性を低減してがんを処置するための改良法
CN104271117A (zh) 利用Lipoplatin治疗癌症的方法
KR20150088237A (ko) 신장 독성이 감소된 개선된 암 치료방법
JP2021525705A (ja) 有機化合物
TWI902129B (zh) 給予kras抑制劑治療癌症
CN121081464A (zh) 小分子抑制剂pz1在治疗kit突变阳性急性髓系白血病中的应用
JP2024525515A (ja) がんの予防用又は治療用の医薬組成物
WO2024211576A1 (en) Immunotherapy formulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150624